I am an experienced Risk Management Business Analyst at a Systemic Greek Bank, with a strong background in finance and risk analysis. I hold an MSc in Applied Risk Management from the University of Athens and have completed the ACA Certificate Level. My expertise lies in financial analysis, risk management, data analysis using SQL, Python, and machine learning tools. I have worked in diverse roles, from assurance to financial analysis and trade operations, across leading firms like EY, PwC, Alpha Bank, and ...

Core Viewpoint - KB Home's shares have declined by 7.9% to $57.81 despite reporting better-than-expected fiscal fourth-quarter earnings and revenue, indicating ongoing challenges in the housing market and a decrease in home deliveries throughout 2025 [1]. Financial Performance - For the fiscal fourth quarter, KB Home reported profits of $1.55 per share, which was below the estimated $1.92, while revenue reached $1.69 billion, exceeding expectations of $1.65 billion [2]. - The company's shares are currently trading below the 160-day moving average, which previously provided support in October and November, and have decreased over 10% in 2025 [2]. Market Activity - There has been an increase in bearish options activity for KB Home, with a 10-day put/call volume ratio of 1.86, placing it in the 84th percentile of its annual range [3]. - On the current trading day, 2,433 puts have been traded, which is 16 times the average intraday volume and more than double the number of calls, with the December 60-strike put being the most popular contract [3].

This audio is auto-generated. Please let us know if you have feedback It’s been another week with far more retail news than there is time in the day. Below, we break down some things you may have missed during the week and what we’re still thinking about. From consumer spending forecasts to Playboy energy drinks, here’s our closeout for the week.What you may have missedLevi’s brings Target vet on boardLevi Strauss & Co. appointed Jeffrey Jones to its board, effective Jan. 21, the company said in a Tuesday ...

Generac Holdings Inc (NYSE:GNRC) stock was last seen up 2.3% at $140.11, after Wells Fargo upgraded the power generator to "overweight" from "equal weight," with a price-target hike to $195 from $186. The firm cited AI data center growth, seeing an opportune buying opportunity after the shares' recent slide. GNRC notched its fifth-straight daily loss yesterday, still down 13.1% since the start of this week. The stock fell below several long-term trendlines during the tumble, now underneath all moving averag ...

Tencent is using a Japanese cloud service to access Nvidia Blackwell chips that remain banned to Chinese customers. ...

ATLANTA, Dec. 19, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Coupang, Inc. (“Coupang” or the “Company”) (NYSE: CPNG). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Coupang’s business, operations, and prospects, including allegations that:  (1) Coupang had inadequate cybersecurity protocols that allowed a former employee to access sensitive customer information for ...

Core Viewpoint - Salarius Pharmaceuticals has adjourned its 2025 Annual Meeting of Stockholders to solicit additional votes due to insufficient quorum, with the meeting reconvened for December 31, 2025 [1][2]. Company Information - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new treatment options for cancer patients, with two drug candidates in its portfolio: seclidemstat and SP-3164 [9]. - Seclidemstat is being studied in a Phase 1/2 clinical trial for hematologic cancers at MD Anderson Cancer Center, targeting myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) [9]. - SP-3164 is an oral small molecule protein degrader currently in the IND stage [9]. - The company has received financial support for its drug candidates from various organizations, including the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas [9]. Meeting Details - The required quorum for the Annual Meeting is 34% of outstanding shares, but only approximately 30% of shares were represented at the time of adjournment [2][3]. - Stockholders eligible to vote are encouraged to do so via the Internet or phone, with the record date for voting remaining October 24, 2025 [3][4]. - The reconvened meeting will be held virtually, allowing stockholders to participate online [2]. Subsidiary Information - Salarius' subsidiary, Decoy Therapeutics Inc., is a preclinical-stage biotechnology company utilizing machine learning and AI tools to develop peptide conjugate drug candidates targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [7]. - Decoy has secured financing from institutional investors and various funding programs, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [7].

Eurozone consumer sentiment unexpectedly weakened in December despite cooling inflation and economic resilience against tariffs, a monthly indicator showed. ...

Few brands have been more associated with the fast-fashion boom of the last two decades than Zara, the flagship apparel chain owned by Spanish clothing giant Inditex SA. It may surprise some consumers to learn, then, that Zara has in fact reduced its global footprint over the last few years since the pandemic. The brand's decline in physical storefronts has been moderate but meaningful, from a third-quarter peak of around 2,139 stores in 2019 to just under 1,800 stores five years later, according to earning ...

Key Takeaways MRNA will get up to $54.3M from CEPI to run a pivotal phase III study of its mRNA-1018 H5 flu vaccine.Moderna's phase III will test safety and immunogenicity in the U.S. and U.K., starting in early 2026.MRNA plans to set aside 20% of H5 vaccine output for low and middle-income countries if approved.Moderna (MRNA) announced that the Coalition for Epidemic Preparedness Innovations (“CEPI”) will invest up to $54.3 million in funding to support a pivotal phase III study evaluating its investigatio ...